Oncotarget

Research Papers:

HIF-1α downregulation and apoptosis in hypoxic prostate tumor cells infected with oncolytic Mammalian Orthoreovirus

Pooja Gupta-Saraf and Cathy L. Miller _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:561-574. https://doi.org/10.18632/oncotarget.1767

Metrics: PDF 1732 views  |   HTML 1708 views  |   ?  


Abstract

Pooja Gupta-Saraf1,2 and Cathy L. Miller1,2,3

1 Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA

2 Interdepartmental Genetics Program, Iowa State University, Ames, IA

3 College of Veterinary Medicine, Iowa State University, Ames, IA

Correspondence:

Cathy L. Miller, email:

Keywords: HIF-1α, hypoxia, prostate cancer, Reovirus, viral oncolysis

Received: January 13, 2014 Accepted: January 29, 2014 Published: January 31, 2014

Abstract

Hypoxia has emerged as one of the most important drivers of tumor aggression, metastasis, and poor clinical outcome in many cancers.In prostate cancer (PCa), hypoxia has been strongly correlated to biochemical failure and local recurrence. However, current PCa treatment options do not address hypoxic cells highlighting a critical gap in existing therapies and the need for development of therapies that target hypoxic prostate tumor cells. Mammalian orthoreovirus (MRV) is an oncolytic virus that targets tumor cells over normal cells which has been shown to be safe and effective against many cancers in vitro, in animal models, and in human clinical trials. We found that MRVinfects and replicates in hypoxic prostate tumor cells to levels comparable to normoxic cells leading to apoptosis and cell death. In addition, the regulatory subunit (HIF-1α) of the master transcriptional regulator of hypoxia, HIF-1, was significantly downregulated in infected cells. HIF-1α downregulation was found to occur via ubiquitin-dependent proteasome-mediated degradation and translational inhibition. Virus-mediated HIF-1α degradation required the HIF-1α PAS domain and expression of the receptor for activated kinase C (RACK1) protein. These data provide evidence that MRV may be a viable therapeutic option for targeting hypoxic cells and HIF-1α in PCa.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1767